PEPTIDES
The present invention relates to novel peptides derived from Melanoma-associated antigen B2 (MAGEB2), complexes comprising such peptides bound to recombinant MHC molecules, and cells presenting said peptide in complex with MHC molecules. Also provided by the present invention are binding moieties that bind to the peptides and/or complexes of the invention. Such moieties are useful for the development of immunotherapeutic reagents for the treatment of diseases such as cancer.
1 . A polypeptide comprising, consisting essentially of or consisting of
(a) the amino acid sequence of any one of SEQ ID NOS: 1-5, or
(b) the amino acid sequence of any one of SEQ ID NOs: 1-5 with the exception of 1, 2 or 3 amino acid substitutions and/or 1, 2 or 3 amino acid insertions, and/or 1, 2 or 3 amino acid deletions,
wherein the polypeptide forms a complex with a Major Histocompatibility Complex (MHC) molecule.
2 . The polypeptide of claim 1 , wherein the polypeptide consists of from 8 to 16 amino acids.
3 . The polypeptide of claim 1 or claim 2 , wherein the polypeptide consists of the amino acid sequence of SEQ ID NOs 1-5.
4 . A complex of the polypeptide of any preceding claim and a Major Histocompatibility Complex (MHC) molecule.
5 . The complex of claim 4 , wherein the MHC molecule is MHC class I.
6 . A nucleic acid molecule comprising a nucleic acid sequence encoding the polypeptide as defined in any one of claims 1 - 3 .
7 . A vector comprising a nucleic acid sequence as defined in claim 6 .
8 . A cell comprising a vector as claimed in claim 7 .
9 . A binding moiety that binds the polypeptide of any one of claims 1 - 3 .
10 . The binding moiety of claim 9 , which binds the polypeptide when it is in complex with MHC.
11 . The binding moiety of claim 10 , wherein the binding moiety is a T cell receptor (TCR) or an antibody.
12 . The binding moiety of claim 11 , wherein the TCR is on the surface of a cell.
13 . A polypeptide as defined in any one of claims 1 - 3 , a complex as defined in claim 4 or claim 5 , a nucleic acid molecule as defined in claim 6 , a vector as defined in claim 7 , a cell as defined in claim 8 or a binding moiety as defined in any one of claims 9 - 12 for use in medicine.
14 . The polypeptide, complex, nucleic acid, vector or cell for use as defined in claim 13 for use in treating or preventing cancer.
15 . A pharmaceutical composition comprising a polypeptide as defined in any one of claims 1 - 3 , a complex as defined in claim 4 or claim 5 , a nucleic acid molecule as defined in claim 6 , a vector as defined in claim 7 , a cell as defined in claim 8 or a binding moiety as defined in any one of claims 9 - 12 together with a pharmaceutically acceptable carrier.
16 . A method of identifying a binding moiety that binds a complex as claimed in claim 4 or claim 5 , the method comprising contacting a candidate binding moiety with the complex and determining whether the candidate binding moiety binds the complex.